Efficacy of erdafitinib in FGFR2/3-altered metastatic urothelial cancer including patients with CDK2NA/B or MTAP loss: Analysis of UNITE study.

被引：0
|
作者：
Jiang, Cindy Y.
Jindal, Tanya
Epstein, Ilana B.
Nguyen, Charles B.
Nizam, Amanda
Bakaloudi, Dimitra Rafailia
Taylor, Amy K.
Milowsky, Matthew I.
Shah, Sumit
Hoimes, Christopher J.
Bilen, Mehmet Asim
Zakharia, Yousef
Emamekhoo, Hamid
Grivas, Petros
Gupta, Shilpa
Bellmunt, Joaquim
Alva, Ajjai Shivaram
Koshkin, Vadim S.
Alhalabi, Omar
Campbell, Matthew T.
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Rogel Comprehens Canc Ctr, Ann Arbor, MI USA
[4] Cleveland Clin, Cleveland, OH 44106 USA
[5] Univ Washington, Dept Med, Div Oncol, Seattle, WA USA
[6] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA
[7] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[8] Stanford Canc Ctr, Stanford, CA USA
[9] Duke Univ, Duke Canc Inst, Durham, NC USA
[10] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[11] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA USA
[12] Univ Wisconsin, Madison, WI USA
[13] Univ Washington, Fred Hutchinson Canc Ctr, Div Hematol Oncol, Dept Med, Seattle, WA 98195 USA
[14] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[15] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI 48109 USA
[16] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[17] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16571
引用
收藏
页数：1
相关论文
共 33 条
  • [1] Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2/3) altered (alt) advanced urothelial cancer (aUC): Analysis of UNITE database
    Jiang, Cindy Y.
    Hwang, Hyunsoo
    Jindal, Tanya
    Qiao, Wei
    Epstein, Ilana
    Nguyen, Charles B.
    Gupta, Shilpa
    Shah, Sumit
    Bilen, Mehmet Asim
    Milowsky, Matthew I.
    Hoimes, Christopher J.
    Kilari, Deepak
    Zakharia, Yousef
    Emamekhoo, Hamid
    Grivas, Petros
    Bellmunt, Joaquim
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    Campbell, Matthew T.
    Alhalabi, Omar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL)
  • [2] Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study.
    Necchi, Andrea
    Todenhoefer, Tilman
    Deville, Jean-Laurent
    Haeckl, Manuel
    Marszewska, Michalina
    McKernan, Phil
    Saulay, Mikael
    Engelhardt, Marc
    De Santis, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [3] First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).
    Siefker-Radtke, Arlene O.
    Necchi, Andrea
    Park, Se Hoon
    GarcAa-Donas, JesAs
    Huddart, Robert A.
    Burgess, Earle Frederick
    Fleming, Mark T.
    Rezazadeh, Arash
    Mellado, Begona
    Varlamov, Sergei
    Joshi, Monika
    Duran, Ignacio
    Tagawa, Scott T.
    OHagan, Anne
    Avadhani, Anjali Narayan
    Zhong, Bob
    De Porre, Peter
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] A first-in-human phase 1b study of a novel allosteric extracellular FGFR2 inhibitor alofanib in patients with refractory metastatic gastric cancer
    Tjulandin, Sergei
    Statsenko, Galina
    Artamonova, Elena
    Vladimirova, Liubov Yu
    Besova, Natalia
    Mochalova, Anastasia
    Rykov, Ivan
    Moiseyenko, Vladimir
    Utyashev, Igor A.
    Iugai, Sergei
    Kazey, Vasily
    Raskin, Grigory
    Dragun, Nadezhda
    Reznikov, Dmitry
    Gavrilova, Evgenia
    Tsimafeyeu, Ilya
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [5] Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study.
    Rosenberg, Jonathan E.
    Gajate, Pablo
    Morales-Barrera, Rafael
    Lee, Jae-Lyun
    Necchi, Andrea
    Penel, Nicolas
    Zagonel, Vittorina
    Sierecki, Mitchell Robert
    Bao, Weichao
    Zhou, Yinghui
    Ellinghaus, Peter
    Sweis, Randy F.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediaterisk non-muscle-invasive bladder cancer (IR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 3 interim analysis.
    Daneshmand, Siamak
    Zaucha, Renata
    Gartrell, Benjamin Adam
    Lotan, Yair
    Hussain, Syed A.
    Lee, Eugene K.
    Procopio, Giuseppe
    Galanternik, Fernando
    Naini, Vahid
    Carcione, Jenna
    Triantos, Spyros
    Baig, Mahadi
    Maranchie, Jodi K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [7] Preliminary data on a phase 1b, first-in-human study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with refractory metastatic gastric cancer.
    Tsimafeyeu, Ilya
    Statsenko, Galina
    Mochalova, Anastasia
    Trenina, Natalia
    Kurakin, Vyacheslav
    Besova, Natalia
    Novoselova, Kristina
    Abramova, Natalia
    Obarevich, Ekaterina
    Kashanova, Alina
    Suetina, Margarita
    Moiseyenko, Vladimir
    Byakhov, Mikhail
    Artamonova, Elena
    Vladimirova, Liubov
    Tjulandin, Sergei
    CANCER RESEARCH, 2021, 81 (13)
  • [8] Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study.
    Apolo, Andrea B.
    Ellerton, John Allan
    Infante, Jeffrey R.
    Agrawal, Manish
    Gordon, Michael S.
    Aljumaily, Raid
    Britten, Carolyn D.
    Dirix, Luc Yves
    Lee, Keun-Wook
    Taylor, Matthew H.
    Schoffski, Patrick
    Wang, Ding
    Ravaud, Alain
    Gelb, Arnold
    Xiong, Junyuan
    Rosen, Galit
    Patel, Manish R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study
    Necchi, A.
    Todenhoefer, T.
    Deville, J-L
    Hackl, M.
    Marszewska, M.
    Mckernan, P.
    Saulay, M.
    Engelhardt, M.
    De Santis, M.
    EUROPEAN UROLOGY, 2023, 83 : S783 - S783
  • [10] Dovitinib as second-line therapy in patients with fibroblast growth factor receptor 2 (FGFR2)-mutated or non-mutated advanced and/or metastatic endometrial cancer (EC): A single-arm, multicenter, phase II study.
    Konecny, Gottfried E.
    Finkler, Neil
    Garcia, Agustin
    Raspagliesi, Francesco
    Lopez, Carolina Muriel
    McCollum, Michael
    Rubio, M. Jesus
    Squires, Matthew
    Pirotta, Nicoletta
    Upalawanna, Allison
    Yovine, Alejandro Javier
    Rocconi, Rodney Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
1234